ACE2	angiotensin-converting enzyme-2
ACE	angiotensin-converting enzyme
ACE1	angiotensin-converting enzyme 1
AIFA	Agenzia Italiana del Farmaco
Alpha	English variant B.1.1.7
Anti-RBD IgG	Immunogloublin G anti receptor-binding domain
Anti-Spike	test igg anti-Spike
BAU	unità arbitrarie vincolanti
Beta variant	(former of South Africa)
BMI	body mass index
CI	intervallo di confidenza
CLIAs	chemiluminescence immunoassay
CRP	C-reactive protein
Delta	Indian variant B.1.617.2
ELISA	enzyme-linked immunosorbent assay
EMA	European Medicines Agency
ETA	variant B.1.525; date of designation Mar-2021
Gamma	Brasilian variant P.1
hACE2 receptor	human angiotensin I-converting enzyme 2 receptor
IFN	Interferon
IgA	Immunoglobulins A
IgG	Immunoglobulins G
IgM	Immunoglobulins M
IOTA	variant B.1.526; earliest documented samples USA (Nov-2020), date of designation Mar-2021
IQR	interquartile range
KAPPA	Indian variant B.1.617.1
LAMBA	variant C.37; earliest documented samples Peru (Aug-2020), date of designation June 2021
LFIAs	lateral flow immunoassays.
MERS	Middle East Respiratory Syndrome
MMF	mycophenolate mofetil
MPA	mycophenolic acid
MPPDH	inosine-5′-monophosphate dehydrogenase
NAAT	nucleic acid amplification test
NGS	Next-Generation Sequencing
bNAbs	Broadly neutralizing antibodies
N-IgG	anti-N-IgG
PRD	viral prion-like domain
RBD	receptor-binding domain
RBDs	receptor-binding domains
RDB-IgG	receptor-binding domain neutralizing antibodies
RT-PCR	real-time PCR Polymerase chain reaction
S	Spike glycoprotein
SARS-CoV-1	Severe Acute Respiratory Syndrome Coronavirus 1
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)
SARSr-CoV Rp3	salivar protein similar to fused 8a and 8b SARS-CoV Beta Coronavirus
S-IgG	anti-Spike IgG
thio-NAD	thionicotinamide-adenine dinucleotide
TNF	tumor necrosis factor
VIPIT	prothrombotic immune thrombocytopenia
VOC	variants of concern
VOI	variants of interest
ZETA	variant P.2